Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H (2017) Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. Breast Cancer Res Treat. doi:10.​1007/​s10549-017-4489-9
2.
3.
Hacioglu B, Akin S, Babacan T, Sever AR, Altundag K (2015) How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission? Future Oncol 11:2799–2801. doi:10.​2217/​fon.​15.​165 CrossRefPubMed
Metadata
Title
Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
Author
Kadri Altundag
Publication date
01-02-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4536-6

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue

Letter to the Editor

Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically

Clinical trial

Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain

Epidemiology

Breast cancer-related paraneoplastic neurologic disease

Clinical trial

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

Clinical trial

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Clinical Trial

The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits